Longitudinal Outcomes and QoL
DISEASE
The median progression-free survival was 46 days [95% confidence interval (CI), 44–48 days]. The median OS was 10.1 months (95% CI, 3.5 months to not reached). No significant difference was observed across dose levels. The median total score of FACT-G first increased from 79.7 [interquartile range (IQR), 65.5–93] at week 1 to 93 (IQR, 88–100) at week 4 and then decreased slightly to 89 (IQR, 78.2–98) at the end of treatment. Similar trends were observed in physical, social/family, emotional, and functional wellbeing. Though statistically nonsignificant, patients’ QoL measured by FACT-G improved by the end of treatment from week 1 in the total score and in physical, social/family, and functional well-being, with the improvement greater in patients who experienced stable disease than in patients whose disease progressed without stabilizing (